Access Program Information
The goal of this clinical research study is to use 68GA-DOTATOC instead of the
standard-of-care 111-In-pentetreotide as a tracer chemical during PET/CT scans for
diagnosing neuroendocrine tumors. A tracer is injected into participant’s bloodstream to
help the study doctor see possible tumors.